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Abstract: EVI1 oncogene expression correlates with chronic myeloid leukaemia 
(CML) progression. Here we show that the knockdown of EVI1 (E) and MDS1-EVI1 
(ME) isoforms reduces cell division at low cell density, inhibits colony forming cells 
(CFC) by 34% and moderately reduces BCR-ABL mRNA and protein expression but 
not tyrosine kinase catalytic activity in K562 cells. We also show that both E and ME 
are expressed in CD34+ selected cells of both CML chronic phase (CML-CP), and 
non CML (normal) origin. Furthermore, EVI1 mRNA and protein expression are 
repressed by imatinib mesylate treatment of CML-CP CD34+ cells, K562 and KY01 
cell lines but has no effect in non CML BCR-ABL –ve CD34+ cells. Together these 
results suggest that BCR-ABL tyrosine kinase catalytic activity regulates EVI1 gene 
expression in CML-CP progenitor cells and that the BCR-ABL oncoprotein partially 
mediates its biological activity through EVI1. EVI1 gene expression in CML-CP 
progenitor cells would provide an in vivo selective advantage, contributing to CML 
pathogenesis. 
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Introduction: Chronic Myeloid Leukaemia (CML) is a disorder of haemopoietic 
stem cells (HSC) [Hamilton et al, 2010], characterised by the Philadelphia (Ph) 
chromosome [Kurzock et al, 1988]. The balanced translocation t(9;22) creates a novel 
fusion gene BCR-ABL [Ben-Neriah et al, 1986] which encodes a spatially [Wetzler et 
al, 1993] and functionally [Konopka et al, 1984] de-regulated tyrosine kinase, BCR-
ABL. BCR-ABL inappropriately activates the MAPK, PI3K and JAK-STAT signal 
transduction pathways [Pendergast et al, 1993; Skorski et al, 1997; Carlesso et al, 
1996] contributing to abnormal myeloid cell proliferation, differentiation, 
transformation and survival [Smith et al 2003]. 
CML usually progresses through three stages, designated chronic (CP), accelerated 
(AP) and terminal blast crisis (BC) phases [Irvine et al, 2010]. CML-CP and CML-
BC phases resemble myeloproliferative disorder and acute leukaemia, respectively; 
the transition between stages is unpredictable, non-time limited and inevitable unless 
treated [Elrick et al 2005]. Imatinib mesylate (IM; Glivec
®
, Novartis Pharma), a 
rationally designed tyrosine kinase inhibitor (TKI) that selectively inhibits BCR-ABL 
tyrosine kinase catalytic activity, is the currently favoured therapeutic agent that 
successfully manages the majority of patients with CML-CP [Valent et al, 2010], 
although it is much less effective when administered at advanced stages (CML-
AP/BC) [O’Hare et al, 2006]. 
The t(9:22) translocation is a CML disease-initiating progenitor cell genetic change, 
the mutation being present in cells at all stages of the disease [Melo and Barnes, 
2007]. Disease progression requires the acquisition of new genetic abnormalities and 
various genes have been implicated in the majority of cases (reviewed in Melo and 
Barnes, 2007). Indeed, enhanced expression of Ecotropic Viral Integration site 1 
(EVI1), a proto-oncogene located on chromosome 3q26, is frequently observed in 
CML-BC [Russell et al, 1993; Carapeti et al, 1996; Ogawa et al, 1996; DeWeer et al, 
2008]. The EVI1 gene encodes a zinc finger transcription factor with important roles 
both in normal development and leukemogenesis [Weiser, 2007]. EVI1 belongs to the 
positive regulatory (PR) domain family and is expressed as multiple naturally 
occurring alternatively spliced variants [Huang, 1999; Alzuherri et al, 2006]. One 
form, designated EVI1 (E), encodes the originally described protein [Morishita et al, 
1990a] whereas another results from splicing of the coding region of the MDS1 gene 
with exon 2 of the EVI1 gene (encoding the PR domain) translating MDS1-EVI1 
(ME) protein [Fears et al, 1996]. Both proteins contain two domains of 7 (ZF1) and 3 
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(ZF2) repeats of the zinc finger motif [Morishita et al, 1988], function as DNA 
binding transcription factors [Weiser, 2007] and contribute to the progression of acute 
leukaemia [Morishita et al, 1992]. Enhanced expression of EVI1 in CML-BC 
implicates this transcription factor in disease progression [Ogawa et al 1996]. 
Previous studies have shown that normal human CD34+ haemopoietic cells express 
EVI1 [Gerhardt et al 1997]. Furthermore, this gene has been shown to have a role in 
self-renewal, proliferation and the repopulating capacity of murine HSC in Evi1 null 
mice [Yuasa et al, 2005]. However, EVI1’s role in CML has not been fully 
determined. EVI1 over-expression in CML-BC has been found in both the presence or 
absence of chromosome 3q26 abnormalities [Morishita et al, 1990b]. Some 
chromosome 3q26 translocations generate enhanced expression of intact EVI1 
including t(3:9;17;22), t(3;7), t(2;3), inv(3) and t(3;8) [DeWeer et al, 2008; Henzan et 
al, 2004; Stevens-Kroef et al, 2004; Suzukawa et al, 1997; Lin et al, 2009] whereas 
others create novel fusion proteins involving TEL t(3;12) [Nakamura et al, 2002] or 
RUNX1 t(3;21) [Mitani et al, 1994]. Many of the same genetic changes are also 
present in poor prognosis acute myeloid leukaemia. 
Between 60-70% of CML-BC cells express EVI1 in the absence of detectable gross 
cytogenetic abnormalities but in these cases it is unclear if expression is a marker or a 
driver of disease [Ogawa et al 1996].
 
These and other studies suggest that EVI1 is not 
expressed in CML-CP mononuclear cells from bone marrow or peripheral blood, but 
CML-CP CD34+ cells have not been previously examined. In this study we have 
investigated EVI1 gene expression, the effect of IM treatment and the biological 
activity of this gene in primary CML-CP CD34+ progenitor cells as well as CML 
derived cell lines. 
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Materials & methods: 
Cell culture K562 and human embryonic kidney (HEK) 293T cells were cultured at 
37°C in 5% CO2 in complete medium (CM) comprising RPMI 1640 or DMEM 
respectively supplemented with 10% foetal calf serum (FCS), 2.5mM glutamine, 
50mg/mL penicillin, 50units/mL streptomycin (all sourced from Lonza Group Ltd, 
Basel, Switzerland), and 200mg/mL Geneticin
®
 (for HEK293T cells only; Invitrogen, 
Paisley, UK). Lentivirus infected cells were selected and maintained in CM and 
2g/mL puromycin (Sigma-Aldrich, St Louis, MO, USA). TKI treated cells were 
incubated with CM supplemented with 5M IM (LC labs, Woburn, MA, USA). 
Hydroxyurea (HU) treated cells were incubated in CM supplemented with 400M 
HU (Sigma-Aldrich). For Colony-Forming Cell (CFC) assays, 1000 cells were plated 
in 1.5mL Methocult
®
 (StemCell Technologies SARL, Grenoble, France) in 30mm 
petridishes and cultured at 37°C, 5% CO2, 12 days. For IM treated CFC assays, 
Methocult
®
 was supplemented with 5M IM. Colonies were counted using an 
inverted microscope (CK2, Olympus UK Ltd, Southend-on Sea, UK).  
Preparation of total cellular RNA, cDNA synthesis and real time quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) RNA was 
prepared from cells at exponential growth phase semi-confluent cultures of cells by 
the Trizol method (Invitrogen). 500ng of total cellular RNA was used to synthesise 
cDNA with the Superscript
®
 III 1
st
 strand synthesis supermix for qPCR according to 
the manufacturer’s instructions (Invitrogen). 5% of the cDNA reaction was used for 
qPCR using ABsolute Blue QPCR mix (ABgene, Epsom, UK), gene specific 
oligonucleotide primers and dual labelled probes, 95°C, 15 min followed by 40 cycles 
95°C, 15 sec, 60°C, 1 min in an OPTICON 2 DNA engine (MJ Research INC, 
Waltham, MA, U.S.A). 
The efficiencies of the qRT-PCR reactions were calculated by using the formula 
Efficiency = -1+10
(-1/slope)
 against the standard curve of each assay over a gradient of 
template concentration with each gene. The efficiency for E, ME and GAPDH 
primers/probes were 112, 115 and 110%. Relative expression levels of E and GAPDH 
or ME and GAPDH were determined using the arithmetic comparative 2
-∆∆Ct 
method 
[Livak et al, 2001] and were determined relative to the calibrators E or ME 
respectively in K562 or CD34+ cells as described.  
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Oligonucleotides Gene specific oligonucleotides were synthesised and supplied 
by Integrated DNA Technologies (Leuven, Belgium) 
5’ Human EVI1: 5’CTTCTTGACTAAAGCCCTTGGA 3’ 
3’ Human EVI1 and MDS1-EVI1: 5’GTACTTGAGCCAGCTTCCAACA 3’ 
5’ Human MDS1-EVI1: 5’GAAAGACCCCAGTTATGGATGG 3’ 
5’ FAM, 3’ TAMRA Human EVI1 and MDS1-EVI1probe: 5’CTTAGACGAATTTT 
ACAATGTGAAGTTCTGCATAG 3’ 
5’ Human GAPDH: 5’CACATGGCCTCCAAGGAGTAA 3’ 
3’ Human GAPDH: 5’TGAGGGTCTCTCTCTTCCTCTTGT 3’ 
5’ 6-FAM, 3’ TAMRA Human GAPDH probe: 5’CTGGACCACCAGCCCCAGCA 
AG 3’. 
5’ Human BCR-ABL: 5’TCCGCTGACCATCAAYAAGGA3’ 
3’ Human BCR-ABL: 5’CACTCAGACCCTGAGGCTCAA3’ 
5’ FAM, 3’ IOWA BLACK Human BCR-ABL probe: 5’CCCTTCAGCGGCCAGTA 
GCATCTGA3’ 
Preparation of plasmid DNA pLKO.1 plasmids (Sigma-Aldrich) HB11 (EVI1 shRNA 
CCGGGCACTACGTCTTCCTTAAATACTCGAGTATTTAAGAAGACGTAGTCT 
TTTT), HB14 (EVI1 shRNA CCGGTGCAGGGTCACTCATCTAAAGCTCGAGCT 
TTAGATGAGTGACCCTGCATTTTT) and NT (MISSION
®
 Non-target shRNA 
control vector) were prepared by affinity chromatography using Nucleobond
®
 
PC500EF gravity flow columns according to manufacturer’s instruction (Macherey-
Nagal GmbH & Co. Kg, Düren, Germany). 
Production of lentivirus and infection of K562 Cells 4-5x10
6
 HEK293T cells 
were cultured in CM supplemented with 10% tetracycline-free FCS (Clontech 
Laboratories Inc., Mountain View CA, USA) as described, and 3g of pLKO.1 
recombinant Lentivirus plasmid DNA, Lenti-X™ HT packaging system (Clontech 
Laboratories Inc.) plasmid DNA transfected using the Lentiphos™ HT system 
(Clontech Laboratories Inc.) according to the manufacturer’s instructions. Virus 
containing cell supernatants were passed through a 0.45m cellulose acetate filter 
(Nalgene company, Rochester, NY, USA) and viral titres determined using the Lenti-
X™ qRT-PCR Titration Kit (Clontech Laboratories Inc.). 2x105 K562 cells were 
transduced at a multiplicity of infection of 40:1 with recombinant Lentivirus in CM 
supplemented with 4g/mL polybrene in 6 well plates. Plates were centrifuged 1200g 
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(Allegra™ X-22R, Beckman Coulter, Inc. Brea, CA, USA) 60 min, 20°C and cultured 
at 37°C, 5% CO2, 24h. Transduced cells were selected in CM supplemented with 
2g/mL puromycin (Sigma-Aldrich). 
Western blotting Protein extracts, SDS polyacrylamide gel electrophoresis and 
Western blotting were performed as described previously [Bartholomew et al, 1997] 
with either -EVI1 (C50E12, Cell Signaling Technology, New England Biolabs, 
Hitchin, UK) or -GAPDH (CA5, Fitzgerald Industries, North Acton, MA, USA) and 
diluted 1/1000 or 1/5000. -c-ABL (2862), -Phospho-CrKL (Tyr207) and -CrKL 
(32H4) were each obtained from Cell Signaling Technology and diluted 1/1000. Anti-
phosphotyrosine (4G10) was obtained from Millipore (Temecula, CA, U.S.A) and 
diluted 1/1000. Appropriate HRP conjugated anti-rabbit or anti-mouse (Sigma-
Aldrich) IgG secondary antibodies were used at 1/5000 dilutions and detection was 
performed by enhanced chemiluminescence (Pierce, Rockford, IL, USA). Relative 
protein quantification was determined by densitometric analysis using Image Lab™ 
Software v3.0 (Bio-Rad laboratories Ltd, Hemel Hempstead, UK.). 
Single cell proliferation assay 1x10
6
 cultured cells were incubated with 1/10 
diluted FITC-labelled CD45 antibody (BD Biosciences, San Jose, CA, USA) for 
15mins, washed with PBS (supplemented with 2% FCS). 50g/mL propidium iodide 
(PI; Sigma-Aldrich) was added and cells immediately washed with PBS/2% FCS. 
Washed cells were re-suspended in 500µL of PBS and single FITC+ / PI negative 
cells isolated by cell sorting (BD FACS Aria, BD Biosciences) were dispensed into 
each well of a 96 well tissue culture plate by the automatic cell dispensing unit 
(ACDU). Cells were monitored by visual inspection using an inverted light 
microscope (CKX41, Olympus UK Ltd) to confirm presence of single cells and daily 
for 4 days for evidence of cell division. All cells dividing at least once were classified 
as proliferating. 
Preparation of primary CD34+ cells  Leukapheresis samples were obtained 
with informed consent as part of the routine assessment of untreated, newly diagnosed 
patients with CML-CP. Non-CML leukapheresis collections were processed as Ph-
negative controls. Samples were enriched to >90% CD34+ progenitors by positive 
selection (CliniMACS
®
, Miltenyi Biotec, Bergisch Gladbach, Germany) and 
cryopreserved. CD34+ cells were cultured at 37°C in 5% CO2 in IMDM (Invitrogen) 
supplemented with serum substitute (bovine serum albumin, insulin and transferrin: 
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‘BIT’, StemCell Technologies), glutamine, penicillin/streptomycin and 5 growth 
factors (IL-3, IL-6, flt3-L, and SCF from StemCell Technologies; G-CSF from 
Chugai Pharma Europe Ltd) as previously described [Jørgensen et al, 2005]. 
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Results: 
 
EVI1 knock down in K562 cells Lentiviral vectors encoding non-target (NT) control 
shRNA and shRNAs targeting EVI1 (HB11 & HB14), were used to create lentivirus 
particles by transient transfection of HEK293T cells as described in Materials and 
methods, and generated virus titres of 6x10
8
/mL (NT), 1.2x10
9
/mL (HB11) and 
3x10
9
/mL (HB14). HB11 is complimentary to part of exon 7 of EVI1 that is 
alternatively spliced to generate EVI1 324 and therefore should not knockdown 
(KD) production of this isoform (Fig.1A). HB14 is complimentary to sequences 
present in all naturally occurring transcripts (3’ untranslated region) and therefore 
should KD all isoforms (Fig.1A). 
Total cellular RNA and proteins derived from puromycin selected cell populations 
from independent cultures of K562 cells infected with each lentivirus were examined 
by qRT-PCR and Western blot analysis to investigate the success of EVI1 KD. The 
results show 60-70% KD of EVI1 gene expression (E and ME transcripts) in K562 
cells with HB11, HB14 or a combination of HB11 and HB14, relative to NT control 
cells (Fig.1B). Western blot analysis showed that production of both 145kDa (E) and 
88kDa (EVI1 324) EVI1 isoforms were significantly repressed (80-90%) by HB14 
or the HB11/HB14 combination whereas only the E protein is repressed by HB11 (70-
80%) (Fig.1C), consistent with the qRT-PCR data and the anticipated specificity of 
the two shRNAs. The ME protein was not detected. Western blot analysis for 
GAPDH detected similar levels of the 35kDa protein showing equal loading of total 
cell protein lysates in each case (Fig. 1C). 
 
EVI1 KD has no significant impact on BCR-ABL  kinase activity To characterise EVI1 
KD K562 cells, we investigated if there was an effect on BCR-ABL at the message, 
protein or catalytic activity (via CrKL phosphorylation) levels. qRT-PCR results 
showed a slight reduction of BCR-ABL gene expression in EVI1 KD K562 with 
HB11, HB14 and HB11/14 infected cells but not in NT control cells (Fig. 2A). The 
same trend was seen by Western blot analysis of BCR-ABL protein levels with -c-
ABL antibodies (Fig. 2B). However, BCR-ABL tyrosine kinase catalytic activity was 
unaffected by EVI1 KD as shown by uniform phosphorylation levels of the BCR-
ABL substrate CrKL in all cells examined (Fig. 2B). The abundance of total CrKL 
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protein was similar in all cells and equal levels of GAPDH confirmed similar protein 
levels in the cell extracts examined (Fig. 2B).  
 
EVI1 KD reduced K562 CFC and single cell proliferation   
To investigate the impact of EVI1 KD on K562 cells, single parental K562, NT 
control and HB14 infected cells were sorted by fluorescence activated cell sorting 
(FACS) into the wells of a 96 well cell culture plate and cell division monitored. The 
results showed that a significantly reduced proportion of the EVI1 KD K562 single 
cells were able to proliferate (Fig.3) and if they did divide, they turned over less 
frequently (data not shown) than parental K562 or NT control cells. These data 
suggest the proliferation capacity of EVI1 KD K562 is reduced. 
We next investigated the functional effect of EVI1 KD by examining the number of 
CFC in semi-solid culture media. The results showed a significant reduction in CFC 
(34%; p<0.0001) in all EVI1 KD cell populations (Fig. 4A) relative to NT control cell 
populations (Fig. 4A). Interestingly, all the colonies produced by the KD cell 
populations were not only fewer in number but also significantly reduced in size (Fig. 
4C &D). These data suggest that EVI1 KD significantly reduces K562 CFC activity.  
 
EVI1 expression in CD34+ cells Previous studies have shown detectable EVI1 
gene transcripts in CML-BC but not CML-CP patient cells [Ogawa et al, 1996]. To 
see if EVI1 expression was detectable in CML-CP, we examined CD34+ selected 
cells derived from the peripheral blood of 3 newly diagnosed patients (demographics 
shown in Table 1) and in one allogeneic normal donor CD34+ as well as CD34+ cells 
from 2 non-CML patients  (collectively designated ‘non-CML’) as controls. E and 
ME expression were normalised to GAPDH, then further scaled to GAPDH 
normalised E or ME calibrator respectively in normal CD34+ cells (sample 010). Both 
E and ME isoforms were readily detected in CD34+ cells, of both CML and non-
CML origin. The relative abundance of both transcripts was similar in CML-CP 
CD34+ cells compared to the non-CML CD34+ cells (Fig. 5A,B). These data show 
that E and ME gene transcripts are readily detected in primitive CML-CP CD34+ 
cells. 
 
EVI1 expression in CML-CP cells and CML cell lines is repressed by IM IM 
treatment has been shown to dramatically reduce the survival of p210 BCR-ABL+ 
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cells in vitro. As EVI1 is a putative survival factor, we were interested to know if 
switching off the kinase survival pathway with IM would have any impact on the 
EVI1 expression in CML-CP CD34+ cells. Interestingly, the results showed a time 
dependent reduction of both E and ME gene expression in IM treated cells relative to 
untreated cells (Fig. 6A,B). The results also showed E and ME expression reduced 
independently of IM when CML-CP CD34+ cells (donor 289) were cultured for 12h 
or more (Fig. 6A,B). However, there was a statistically very significant reduction of E 
and ME in IM treated cells, relative to cells cultured in growth medium alone, at both 
12 (E p <0.0008, ME p<0.0086) and 24h (E p <0.0001, ME p<0.0009) (Fig. 6A,B). E 
and ME expression was also examined in non-CML CD34+ cells (donor 019) + and – 
IM. IM treatment has no effect on EVI1 expression in these BCR-ABL –ve CD34+ 
cells although once again expression is slightly decreased following 12 hrs or more of 
cells in culture in the presence or absence of the TKI (Fig. 6 C,D). 
To confirm the effect of IM on EVI1 gene and protein expression we examined its 
impact in CML derived cell lines K562 and KY01. Both E and ME isoforms were 
dramatically reduced after 6 h and continued to be repressed further for the time 
points shown (>90% after 24 h, Fig. 7A) in K562. The same IM mediated repression 
of E and ME isoforms was also observed in another CML derived cell line, KYO1 
(Fig. 7B). Western blot analysis detected the 145kDa E protein in both cell lines (Fig. 
7C), The abundance of the 145kDa E protein rapidly diminished within 6 h of IM 
treatment and further reduced after 24 h (Fig. 7C, 70%-90% reduction after 24hrs), 
consistent with the qRT-PCR data. IM treatment for 24hrs inhibits phosphorylation of 
BCR-ABL (Fig. 7D). Furthermore, inhibition of BCR-ABL catalytic activity is 
observed after 6hrs IM treatment and is sustained for at least 24hrs, as observed by 
dramatically reduced phosphorylation of the CrKL substrate protein (Fig. 7E). Cell 
counting of trypan blue (Sigma-Aldrich) treated cells demonstrated that 5M IM 
treatment inhibited K562 proliferation but had no effect on cell viability over the 24hr 
period examined (data not shown). 
To see if the impact of IM on EVI1 was specific, or a more general consequence of 
inhibiting cell proliferation, we examined the effect of hydroxyurea (HU) in K562 
cells. Western blot analysis shows no major change in the 145ka E protein following 
treatment of K562 cells with HU for up to 24hrs (Fig. 7C). 
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Our data show that IM rapidly inhibits EVI1 gene expression in primary CML-CP 
CD34+ cells and CML derived cell lines. Furthermore EVI1 KD significantly reduces 
K562 CFC activity (Fig.4A); this compares with an 80% reduction in K562 CFC 
achieved following IM (5M) treatment (Fig. 4B). Together these data suggest EVI1 
repression could partially mediate the cellular response to IM. 
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Discussion:  
We have shown that EVI1 has a role in cell proliferation in Ph+ cells. KD of EVI1 in 
K562 cells reduced their proliferative capacity in CFC as well as single cell 
proliferation assays. These observations were the same for KD either of all EVI1 
isoforms (with HB14 treated cells) or when EVI1324 expression only was retained 
(HB11 treated cells), showing this latter truncated protein, which lacks transforming 
activity [Kilbey and Bartholomew, 1998] cannot compensate for reduced E and ME 
isoforms. It is possible that our studies underestimate the impact of EVI1 repression 
due to partial KD only since other studies, including Evi1 K.O mice show a more 
severe effect on HSC numbers [Yuasa et al, 2005] and an almost complete cell cycle 
arrest is reported in EVI1 KD K562 cells by Lugthart et al (2011). 
The ME 185kDa protein is not detected in K562 or KY01 cells using -EVI1  
antibody despite qRT-PCR data demonstrating RNA expression of this isoform. It is 
currently unclear if the ME protein is not produced in K562 cells or is at levels below 
the detection limits of our assays. This study might have underestimated the 
abundance of E encoding transcripts as there are multiple transcription initiation sites 
(1a, 1b, 1c and 3L) which are not detected by the specific primers and probe set used 
here [Aytekin et al, 2005; Lugthart et al, 2008]. Expression of E alone is associated 
with poor prognosis acute leukaemia [Barjesteh et al, 2003]. Therefore higher levels 
of E relative to ME would be likely to contribute to disease progression. A similar 
observation has been made for another PR family gene RIZ where the shorter PR 
domain deleted forms are always found in chromosome 1p36 linked malignancies, 
consistent with the view that the long PR domain containing forms have tumour 
suppressor activity [Huang, 1999]. 
We also show here that EVI1 expression is not only seen in K562 and KY01 cell lines 
but in primary CML-CP cells also whereas previous reports have suggested it is only 
observed in CML-BC [Ogawa et al, 1996]. It is likely that the discrepancy between 
our results and previous data are due to increased sensitivity of detection resulting 
from the analysis of a CD34+ subpopulation of peripheral blood mononuclear cells, 
which express the highest levels of EVI1. Both CD34+ non-CML cells and CD34+ 
CML cells express similar levels of both E and ME gene transcripts. Previous studies 
show both isoforms are present in normal tissues [Fears et al, 1996; Wimmer et al, 
1998]. Only one of the samples in this study, donor 010, was normal but the relative 
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abundance of both transcripts was similar here to that of the other non-CML and 
CML samples examined. Therefore, these data show: i) that CD34+ cells express high 
levels of EVI1 and ii) that both transcripts are present in CML cells at similar levels to 
normal and non CML cells. 
In this study we observed that EVI1 KD had no effect on BCR-ABL kinase activity, 
so we next switched–off the oncogenic catalytic kinase by treatment with the TKI, 
IM. IM mediated inhibition of BCR-ABL resulted in a rapid repression of both ME 
and E EVI1 gene expression in CML CD34+, K562 and KY01 cells. This effect is 
likely to be specific as IM treatment has no effect on EVI1 expression in BCR-ABL    
-ve non-CML CD34+ cells (Fig.6C,D). Western blot analysis showed a dramatic 
reduction of the 145kDa E protein in IM-treated K562 and KY01 cells. This 
repression was not a consequence of general inhibition of cell proliferation but BCR-
ABL specific as treatment with the anti-metabolite, hydroxyurea did not alter E 
protein levels. Furthermore, this was not the result of general cell toxicity as trypan 
blue exclusion studies show the cells retained viability for at least 24hrs of IM 
treatment and there was no impact on cellular levels of numerous other proteins 
examined, including CrKL, GAPDH, STAT5, ERK1/2, AKT and BCR-ABL (data 
not shown). 
As was seen for K562 cell line, IM mediated inhibition of BCR-ABL results in a 
rapid decline in EVI1 gene expression at both the mRNA and protein level in primary 
CML-CP cells. EVI1 expression also declines by 50% following culture of primary 
CML-CP cells for 12-24 h. This reduction is not as great as in the presence of IM and 
might reflect maturation of cells or ex-vivo culture not adequately replicating in vivo 
conditions. A similar partial decline in EVI1 expression is also observed in non-CML 
CD34+ cells cultured for 12 hrs or more. 
Inhibition of EVI1 expression by IM demonstrates for the first time that its expression 
is regulated in BCR-ABL+ cells by the catalytic activity of this aberrant kinase. 
Regulation of mRNA expression is rapid, suggesting it is a direct response to 
inhibition of tyrosine kinase mediated signaling from the BCR-ABL protein. Several 
studies have identified many potential BCR-ABL target genes previously but EVI1 
was not described [Håkansson et al, 2008; Nunoda et al, 2007; Bianchini et al, 2007]. 
This study represents the first report of a signal transduction pathway that regulates 
EVI1 gene expression. Although BCR-ABL transmits an aberrant signal, these results 
suggest EVI1 expression is modulated by one or more of the three major pathways, 
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JAK-STAT, MAPK or PI3K activated by this promiscuous kinase [Pendergast et al, 
1993; Skorski et al, 1997; Carlesso et al, 1996]. The particular pathway involved is 
currently under investigation. The molecular basis of BCR-ABL mediated EVI1 
regulation should facilitate how expression of this developmentally important gene is 
controlled in HSC and other tissues where it is normally expressed [Yuasa et al, 2005; 
Goyama et al, 2008, Hoyt et al, 1997]. 
These data establish a link between BCR-ABL kinase catalytic activity and EVI1 gene 
expression. We propose that BCR-ABL positively regulates EVI1 gene expression. 
The level of EVI1 gene expression is not elevated by BCR-ABL kinase relative to 
expression levels observed in non-CML and normal primitive haemopoetic cells. 
However, it is deregulated since the mechanism regulating EVI1 gene expression in 
normal CD34+ cells is distinct from that in CML-CP CD34+ cells since in the latter 
expression is dependent upon BCR-ABL catalytic activity. The BCR-ABL kinase 
might activate a pathway that normally regulates EVI1 production in primitive 
haemopoietic cells. Since BCR-ABL kinase is constitutively active, it will 
continuously stimulate the pathway leading to sustained de-regulated EVI1 gene 
expression. It is unlikely that EVI1 expression is repressed by inhibition of other 
receptors (PDGFR, PDGFR or c-KIT) that are known to be inactivated by IM 
[Fabbro et al, 1999] because IM has no effect on BCR-ABL –ve CD34+ cells (Fig. 
6C,D).  
Maintenance of EVI1 expression in primitive HSC is likely a selective advantage. 
Retroviral tagging studies show that proviral insertions are frequently seen in the 
EVI1 locus in dominant non-malignant HSC clones retrieved from transplant 
recipients [Kustikova et al, 2005] and primary myeloid CD34+ ex-vivo cultures are 
enriched for viral insertions in this gene [Sellers et al, 2010]. Furthermore, EVI1 is 
required for the survival and proliferation of HSC [Yuasa et al, 2005; Goyama et al, 
2008]. The EVI1 KD studies in K562 cells described above support this notion as 
these cells show a reduced proliferative capacity in CFC and single cell proliferation 
assays. Our results suggest that BCR-ABL tyrosine kinase catalytic activity sustains 
EVI1 gene expression in CML-CP CD34+ cells and that this gives cells a selective 
advantage in a manner analogous to retroviral insertion. It is possible the impact of 
EVI1 KD in primary CML-CP cells would be even greater than we see with K562 
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cells which is an immortal cell line with a number of additional genetic abnormalities. 
We are currently investigating this. 
Sustained expression of EVI1 could be one of the mechanisms by which BCR-ABL 
contributes a selective advantage to primitive haemopoietic cells in CML, resulting in 
an increased production of mature cells in peripheral blood. In this case gross 
chromosome abnormalities are not required as the BCR-ABL mutation causes de-
regulation of EVI1 gene expression. Interestingly, EVI1 translocations are frequently 
observed in CML patients treated with TKI inhibitors that progress to blast crisis 
[Paquette et al, 2011] and enhanced EVI1 expression is a predictor of poor prognosis 
in TKI resistant chronic phase CML [Daghistani et al, 2010]. This suggests that 
inhibition of BCR-ABL kinase may select for cells that de-regulate EVI1 expression 
by alternative mechanisms. Mutations causing elevated levels of EVI1, E relative to 
ME, or its fusion proteins which can occur in CML-BC might be necessary for other 
EVI1 mediated biological activities including inhibition of terminal cell 
differentiation. Indeed, previous studies show that EVI1 mediated inhibition of 
granulocyte differentiation is dependent on the level of expression [Khanna-Gupta et 
al, 1996]. Our results suggest BCR-ABL mediated EVI1/MDS1-EVI1 gene expression 
represents a novel mechanism of de-regulating this gene in leukaemia. 
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Tables: 
 
Table 1 
Shows sex, age and diagnosis of donor CD34+ cell samples used for qRT-PCR 
analysis. Not available N/A. 
 
Table 1 
 
Patient ID Sex Age Diagnosis 
    
010 M 45 Normal donor 
011 F 51 Multiple myeloma 
012 F 61 Mantle cell lymphoma 
019 M 62 Mantle cell lymphoma 
249 N/A N/A CML 
255 F 46 CML 
257 M 47 CML 
289 F 47 CML 
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Figure legends: 
Fig. 1 EVI1/MDS1-EVI1 knockdown in K562 cells. (A) Shows a schematic 
representation of the four indicated natural EVI1 isoforms. The position of shRNA 
homology for HB11 and HB14 are indicated by thick horizontal lines showing that 
HB11 is complimentary to sequences located in exon 7 present in all transcripts 
except EVI1324 and HB14 is complimentary to sequences located in the 3’ 
untranslated region of all transcripts. The coding exons 3 to 16 are numbered and 
indicated by boxes as described previously [Alzuherri et al, 2006]. The EVI1 exon 2 
and MDS1 are also boxed and indicated for MDS1-EVI1. Splice variant deleted exons 
are shown in black boxes. Both introns and 3’ untranslated regions are shown by 
horizontal lines that connect exons. (B) Shows histogram of EVI1 (white bars) or 
MDS1-EVI1 (black bars) mRNA levels normalised for GAPDH mRNA for the 
indicated cell populations relative to the K562 calibrator for EVI1 (GAPDH 
normalised EVI1) or MDS1-EVI1 (GAPDH normalised MDS1-EVI1) respectively, as 
determined by qRT-PCR. Columns are the mean of an experiment performed in 
quadruplicate and the error bars the standard deviation. (C) shows Western blot 
analysis of the indicated whole cell protein extracts using -EVI1 and –GAPDH 
antibodies. The position of the 145kDa EVI1, 88kDa 324 and 35kDa GAPDH 
proteins are indicated by arrow. 
 
Fig. 2 BCR-ABL expression and catalytic activity in K562, NT, HB11, HB14 and 
HB(11+14) cells. (A) Shows histogram of BCR-ABL mRNA levels normalised for 
GAPDH mRNA relative to GAPDH normalised BCR-ABL mRNA in K562 cells 
(calibrator) for the indicated cell populations, determined by qRT-PCR. Columns are 
the mean of an experiment performed in quadruplicate and the error bars the standard 
deviation. (B) shows Western blot analysis of the indicated whole cell protein extracts 
using -c-ABL, -Phospho-CrKL (Tyr207), -CrKL and –GAPDH antibodies. The 
position of the 145kDa EVI1, 88kDa 324 and 35kDa GAPDH proteins are indicated 
by arrow. 
 
 
Fig. 3 K562 and HB14 KD single cell proliferation assay. Histogram shows the 
percentage undivided single cells at 0 to 4 days of culture. At day 0 all single cells in 
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96 well plates are undivided, giving a value of 100%. Black bars are K562 cells, grey 
bars NT cells and white bars HB14. All K562 and NT cells have divided at least once 
by day 4 compared to only 50% of HB14 cells. The results shown are the mean of an 
experiment performed twice. 
 
Fig. 4 Colony forming activity of K562 and derivative EVI1 KD cells. (A) Shows 
the number of CFC per 1000 cells plated for the indicated cell populations. Each CFC 
assay was performed in triplicate for the indicated cell population and the results 
shown are a typical example of an experiment performed four times. *** p<0.0001. 
(B) The same as (A) for K562 cells + or – 5M IM. (C) Image shows typical colonies 
formed by the indicated cell populations. (D) Histogram showing mean colony 
diameter of indicated cell population as a % of mean K562 colony diameter. Error 
bars are the standard deviation.  n=20 for the total number of each cell colony type 
analysed. 
 
Fig. 5 EVI1 (white bars) and MDS1-EVI1 (black bars) gene expression in the 
indicated donor Ph- CD34+ non-CML cells (donor 011,012) and Ph+ CD34+ CML-
CP cells (donor 249,255,257). Shows histograms of EVI1 and MDS1-EVI1 mRNA 
levels normalised for GAPDH mRNA relative to GAPDH normalised EVI1 or MDS1-
EVI1 mRNA respectively of calibrator cells (Ph- CD34+ normal cells 010), 
determined by qRT-PCR. Columns are the mean of an experiment performed in 
quadruplicate and the error bars the standard deviation.  
 
Fig. 6 EVI1 (white bars) and MDS1-EVI1 (black bars) gene expression in donor 289 
Ph+ CML-CP cells and Ph- donor 019 cells exposed to 5M IM for various times. 
Shows histograms of EVI1 (A,C) and MDS1-EVI1 (B,D) mRNA levels normalised for 
GAPDH mRNA relative to GAPDH normalised EVI1 (A,C) or MDS1-EVI1 (B,D) 
mRNA in calibrator cells (0 hrs, untreated donor 289 [A,B] or 019 [C,D])  
respectively, in the presence (+) or absence (-) of 5M IM for 6, 12 and 24h  
determined by qRT-PCR. Columns are the mean of an experiment performed in 
quadruplicate and the error bars the standard deviation. 
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Fig. 7 Shows EVI1 and MDS1-EVI1 mRNA levels in K562 (A) and KY01 (B) 
treated with 5M IM for the time indicated. Analysis as described in legend to figure 
1 with untreated 0hr K562 (A) or KY01 (B) as calibrator. (C) shows Western blot 
analysis of whole cell protein extracts derived from cells treated with either 5M IM 
(K562 and KY01) or 400M HU for the indicated time using -EVI1 and –GAPDH 
antibodies. Also shown are Western blot analysis of whole cell protein extracts 
derived from IM treated (+) or untreated (-) cells for the indicated times with -
phosphotyrosine, -c-ABL and -GAPDH (D) and -pCrKL, -CrKL and -
GAPDH (E) antibodies. 
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